Fig. 7

U2AF2 was more highly expressed in gliomas, and was correlated with poor survival and transcriptionally regulated by ISL2. a The mRNA expression of U2AF2 according to WHO grades, GBM, and LGG, IDH status, and the prognostic significance of U2AF2 were shown in TCGA database. b The mRNA expression of U2AF2 according to WHO grades, GBM and LGG, IDH status, and the prognostic significance of U2AF2 were shown in the CGGA database. c, d, f U2AF2 was expressed at higher levels in different grades of glioma tissues, compared with NBT as determined by qPCR (c), western blotting (d) and immunohistochemistry (f). (grade II, n = 20; grade III, n = 25; grade IV, n = 25; NBT n = 10). Scale bar = 50 μm. e Kaplan-Meier analysis showed the prognostic significance of 70 glioma patients with high versus low U2AF2 expressions detected by immunohistochemistry. g Schematic diagram of the putative ISL2 binding site in the 3′-UTR of U2AF2. h The luciferase reporter assays showed that ISL2 knockdown (left) or overexpression (right) altered the luciferase promoter activities of U2AF2. i The ChIP qPCR showed that ISL2 bound to the promoter of U2AF2. j, k The western blot (j) and qPCR (k) showed that the expression of U2AF2 in GSCs after ISL2 knockdown (left) or overexpression (right). EV: empty vector, OE: overexpression, NC: negative control, KD: knockdown. All data are shown as the mean ± SD (three independent experiments). ^*p < 0.05; ^**p < 0.01; ^***p < 0.001